Single dose nonavalent HPV vaccine – need of the hour | Zendy

Soma Bandyopadhyay | Zendy; Manidip Pal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Single dose nonavalent HPV vaccine – need of the hour

Author(s) -

Soma Bandyopadhyay,

Manidip Pal

Publication year - 2020

Publication title -

deleted journal

Language(s) - English

Resource type - Journals

ISSN - 2091-0800

DOI - 10.3126/nje.v10i2.28962

Subject(s) - medicine , vaccination , herd immunity , girl , cervix , immunity , pediatrics , virology , immunology , immune system , cancer , psychology , developmental psychology

Human Papilloma Virus (HPV) vaccination of the preadolescent (9-14 years) females is the potential solution to eradicate carcinoma cervix. Nonavalent vaccine provides wider coverage than the quadrivalent vaccine. On long-term follow-up, even after single-dose HPV vaccination, the antibody titer remains good. Herd immunity can also be achieved by HPV vaccination. Hence, mass single-dose nonavalent HPV vaccination for sexually naive preadolescent girls can provide almost 100% protections and a cost-effective approach for the developing countries.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research